The effect of obesity on chronic kidney disease

Journal of Renal Nutrition

Volumn 21, Issue 1, 2011, Pages 66-71

  Kopple, Joel D ^a,b   Feroze, Usama ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINURIA; CHRONIC DISEASE; DIABETIC NEPHROPATHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; OBESITY; REVIEW;

ALBUMINURIA; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; KIDNEY DISEASES; OBESITY;

EID: 78650698852     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2010.10.009     Document Type: Review

References (79)

1. Must A. Morbidity and mortality associated with elevated body weight in children and adolescents. Am J Clin Nutr 1996, 63:445S-447S.
2. Olshansky S.J., Passaro D.J., Hershow R.C., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005, 352:1138-1145.
3. Mann C.C. Public health. Provocative study says obesity may reduce U.S. life expectancy. Science 2005, 307:1716-1717.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106:3143-3421.
5. Hafidh S., Senkottaiyan N., Villarreal D., et al. Management of the metabolic syndrome. Am J Med Sci 2005, 330:343-351.
6. Govindarajan G., Whaley-Connell A., Mugo M., et al. The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci 2005, 330:311-318.
7. Weisinger J.R., Kempson R.L., Eldridge F.L., et al. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med 1974, 81:440-447.
8. Wannamethee S.G., Shaper A.G. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999, 22:1266-1272.
9. Wolf H.K., Tuomilehto J., Kuulasmaa K., et al. Blood pressure levels in the 41 populations of the WHO MONICA project. J Hum Hypertens 1997, 11:733-742.
10. Souraty P., Nast C.C., Mehrotra R., et al. Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes. Nat Clin Pract Nephrol 2008, 4:639-642.
11. Reeves G.K., Pirie K., Beral V., et al. Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ 2007, 335:1134.
12. Renehan A.G., Tyson M., Egger M., et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
13. Adams K.F., Leitzmann M.F., Albanes D., et al. Body size and renal cell cancer incidence in a large us cohort study. Am J Epidemiol 2008, 168:268-277.
14. Curhan G.C., Willett W.C., Rimm E.B., et al. Body size and risk of kidney stones. J Am Soc Nephrol 1998, 9:1645-1652.
15. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811-1821.
16. Hamano S., Nakatsu H., Suzuki N., et al. Kidney stone disease and risk factors for coronary heart disease. Int J Urol 2005, 12:859-863.
17. Obligado S.H., Goldfarb D.S. The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 2008, 21:257-264.
18. Taylor E.N., Stampfer M.J., Curhan G.C. Obesity, weight gain, and the risk of kidney stones. JAMA 2005, 293:455-462.
19. Taylor E.N., Stampfer M.J., Curhan G.C. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 2005, 68:1230-1235.
20. Shen W.W., Chen H.M., Chen H., et al. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol 2010, 5:1401-1409.
21. Bonnet F., Deprele C., Sassolas A., et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IGA nephritis. Am J Kidney Dis 2001, 37:720-727.
22. Gonzalez E., Gutierrez E., Morales E., et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int 2005, 68:263-270.
23. Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant 2005, 20:2594-2597.
24. Wang Y., Chen X., Song Y., et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008, 73:19-33.
25. Hsu C.Y., McCulloch C.E., Iribarren C., et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006, 144:21-28.
26. Praga M., Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens 2006, 15:481-486.
27. Kurella M., Lo J.C., Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005, 16:2134-2140.
28. Elsayed E.F., Tighiouart H., Weiner D.E., et al. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis 2008, 52:49-57.
29. Ryu S., Chang Y., Woo H.Y., et al. Changes in body weight predict CKD in healthy men. J Am Soc Nephrol 2008, 19:1798-1805.
30. Iseki K., Ikemiya Y., Kinjo K., et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004, 65:1870-1876.
31. Navaneethan S.D., Yehnert H., Moustarah F., et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4:1565-1574.
32. Morales E., Valero M.A., Leon M., et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003, 41:319-327.
33. Praga M., Hernandez E., Andres A., et al. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron 1995, 70:35-41.
34. Praga M., Hernandez E., Herrero J.C., et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000, 58:2111-2118.
35. Kalantar-Zadeh K., Kopple J.D. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 2006, 151:57-69.
36. Kalantar-Zadeh K., Abbott K.C., Salahudeen A.K., et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005, 81:543-554.
37. Leavey S.F., McCullough K., Hecking E., et al. Body mass index and mortality in " healthier" as compared with " sicker" haemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant 2001, 16:2386-2394.
38. Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med 2008, 86:729-734.
39. Kurukulasuriya L.R., Stas S., Lastra G., et al. Hypertension in obesity. Endocrinol Metab Clin North Am 2008, 37:647-662. ix.
40. Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens 2006, 15:173-178.
41. Sarzani R., Salvi F., Dessi-Fulgheri P., et al. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008, 26:831-843.
42. Dornfeld L.P., Maxwell M.H., Waks A., et al. Mechanisms of hypertension in obesity. Kidney Int Suppl 1987, 22:S254-S258.
43. Sharma A.M., Engeli S., Pischon T. New developments in mechanisms of obesity-induced hypertension: role of adipose tissue. Curr Hypertens Rep 2001, 3:152-156.
44. Cooper R., McFarlane-Anderson N., Bennett F.I., et al. Ace, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 1997, 11:107-111.
45. Rossi G.P., Belfiore A., Bernini G., et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008, 93:2566-2571.
46. Fujita T. Aldosterone and CKD in metabolic syndrome. Curr Hypertens Rep 2008, 10:421-423.
47. Dessi-Fulgheri P., Sarzani R., Tamburrini P., et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens 1997, 15:1695-1699.
48. Olsen M.H., Hansen T.W., Christensen M.K., et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005, 46:660-666.
49. St Peter J.V., Hartley G.G., Murakami M.M., et al. B-type natriuretic peptide (BNP) and n-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. Clin Chem 2006, 52:680-685.
50. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004, 109:594-600.
51. De Pergola G., Garruti G., Giorgino F., et al. Reduced effectiveness of atrial natriuretic factor in pre-menopausal obese women. Int J Obes Relat Metab Disord 1994, 18:93-97.
52. Kaaja R.J., Poyhonen-Alho M.K. Insulin resistance and sympathetic overactivity in women. J Hypertens 2006, 24:131-141.
53. Scherrer U., Randin D., Tappy L., et al. Body fat and sympathetic nerve activity in healthy subjects. Circulation 1994, 89:2634-2640.
54. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006, 24:789-801.
55. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 2001, 19:523-528.
56. Modan M., Halkin H., Almog S., et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985, 75:809-817.
57. Katzeff H.L. Increasing age impairs the thyroid hormone response to overfeeding. Proc Soc Exp Biol Med 1990, 194:198-203.
58. Grassi G., Facchini A., Trevano F.Q., et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005, 46:321-325.
59. Shamsuzzaman A.S., Gersh B.J., Somers V.K. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003, 290:1906-1914.
60. Peppard P.E., Young T., Palta M., et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342:1378-1384.
61. Ip M.S., Lam B., Ng M.M., et al. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002, 165:670-676.
62. Phillips B.G., Kato M., Narkiewicz K., et al. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol 2000, 279:H234-H237.
63. Baguet J.P., Narkiewicz K., Mallion J.M. Update on hypertension management: obstructive sleep apnea and hypertension. J Hypertens 2006, 24:205-208.
64. Narkiewicz K., Kato M., Phillips B.G., et al. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 1999, 100:2332-2335.
65. Zheng Y., Yamada H., Sakamoto K., et al. Roles of insulin receptor substrates in insulin-induced stimulation of renal proximal bicarbonate absorption. J Am Soc Nephrol 2005, 16:2288-2295.
66. Brook R.D., Bard R.L., Rubenfire M., et al. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 2001, 88:1264-1269.
67. Furukawa S., Fujita T., Shimabukuro M., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
68. Sharma A.M. Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 2002, 26(suppl 4):S5-S7.
69. Pierce G.L., Beske S.D., Lawson B.R., et al. Weight loss alone improves conduit and resistance artery endothelial function in young and older overweight/obese adults. Hypertension 2008, 52:72-79.
70. Haynes W.G., Morgan D.A., Walsh S.A., et al. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 100:270-278.
71. Patel S.B., Reams G.P., Spear R.M., et al. Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep 2008, 10:131-137.
72. Rocchini A.P., Key J., Bondie D., et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989, 321:580-585.
73. Wofford M.R., Hall J.E. Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004, 10:3621-3637.
74. Festa A., D'Agostino R., Howard G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 2000, 102:42-47.
75. Kabir A.A., Whelton P.K., Khan M.M., et al. Association of symptoms of depression and obesity with hypertension: the Bogalusa Heart Study. Am J Hypertens 2006, 19:639-645.
76. Blaine B. Does depression cause obesity? A meta-analysis of longitudinal studies of depression and weight control. J Health Psychol 2008, 13:1190-1197.
77. Hedayati S.S., Bosworth H.B., Briley L.P., et al. Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int 2008, 74:930-936.
78. Cukor D., Coplan J., Brown C., et al. Course of depression and anxiety diagnosis in patients treated with hemodialysis: a 16-month follow-up. Clin J Am Soc Nephrol 2008, 3:1752-1758.
79. Klein S., Fontana L., Young V.L., et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004, 350:2549-2557.